Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $7.97 and last traded at $8.09, with a volume of 400639 shares trading hands. The stock had previously closed at $8.43.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on FOLD shares. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Amicus Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $16.75.
Read Our Latest Report on Amicus Therapeutics
Amicus Therapeutics Price Performance
The firm has a market capitalization of $2.45 billion, a PE ratio of -44.39, a P/E/G ratio of 1.51 and a beta of 0.69. The firm's fifty day moving average price is $9.19 and its 200 day moving average price is $9.90. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01.
Institutional Investors Weigh In On Amicus Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. Virtus Fund Advisers LLC purchased a new position in shares of Amicus Therapeutics during the 4th quarter valued at about $29,000. Covestor Ltd grew its holdings in Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Amicus Therapeutics during the third quarter valued at approximately $55,000. GF Fund Management CO. LTD. acquired a new position in Amicus Therapeutics in the fourth quarter valued at approximately $59,000. Finally, R Squared Ltd purchased a new stake in Amicus Therapeutics in the 4th quarter worth approximately $79,000.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Further Reading
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
